| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 16 | 2022 | 359 | 2.220 |
Why?
|
| Erythroid Precursor Cells | 18 | 2013 | 33 | 1.980 |
Why?
|
| Erythroblasts | 13 | 2019 | 25 | 1.850 |
Why?
|
| Hematopoietic Stem Cells | 13 | 2019 | 305 | 1.320 |
Why?
|
| Multiple Myeloma | 7 | 2019 | 331 | 1.300 |
Why?
|
| Erythropoietin | 14 | 2012 | 90 | 1.250 |
Why?
|
| GTPase-Activating Proteins | 3 | 2019 | 67 | 1.220 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2022 | 665 | 1.170 |
Why?
|
| Erythropoiesis | 14 | 2020 | 51 | 1.130 |
Why?
|
| Hematopoiesis | 9 | 2022 | 168 | 1.020 |
Why?
|
| Cord Blood Stem Cell Transplantation | 6 | 2016 | 91 | 0.900 |
Why?
|
| DNA-Binding Proteins | 7 | 2022 | 1244 | 0.880 |
Why?
|
| Signal Transduction | 16 | 2019 | 3397 | 0.840 |
Why?
|
| Transplantation Conditioning | 13 | 2017 | 372 | 0.820 |
Why?
|
| Histones | 4 | 2020 | 333 | 0.810 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2022 | 798 | 0.810 |
Why?
|
| Erythrocytes | 8 | 2013 | 254 | 0.780 |
Why?
|
| Gene Expression Regulation | 11 | 2021 | 1983 | 0.750 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 520 | 0.730 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 46 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2017 | 889 | 0.650 |
Why?
|
| Stem Cell Factor | 6 | 2012 | 19 | 0.630 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 60 | 0.630 |
Why?
|
| Folate Receptor 2 | 1 | 2018 | 1 | 0.620 |
Why?
|
| Folate Receptor 1 | 1 | 2018 | 2 | 0.620 |
Why?
|
| Transcriptional Activation | 2 | 2019 | 294 | 0.610 |
Why?
|
| Cell Differentiation | 20 | 2019 | 1529 | 0.610 |
Why?
|
| Phosphorylation | 11 | 2019 | 1130 | 0.610 |
Why?
|
| Apoptosis | 16 | 2017 | 1717 | 0.600 |
Why?
|
| Dioxygenases | 5 | 2022 | 77 | 0.590 |
Why?
|
| Plasma Cells | 2 | 2018 | 84 | 0.590 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2327 | 0.590 |
Why?
|
| Tretinoin | 1 | 2018 | 128 | 0.580 |
Why?
|
| Megakaryocytes | 4 | 2018 | 36 | 0.540 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2008 | 69 | 0.510 |
Why?
|
| Erythroid Cells | 4 | 2013 | 14 | 0.510 |
Why?
|
| Cytokines | 1 | 2019 | 806 | 0.490 |
Why?
|
| Cell Nucleus | 5 | 2019 | 602 | 0.460 |
Why?
|
| Humans | 86 | 2022 | 89613 | 0.440 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2012 | 65 | 0.440 |
Why?
|
| Nuclear Proteins | 7 | 2016 | 727 | 0.430 |
Why?
|
| Plasmodium falciparum | 2 | 2011 | 47 | 0.420 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2011 | 10 | 0.390 |
Why?
|
| Transcription Factors | 5 | 2013 | 1663 | 0.390 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 1446 | 0.380 |
Why?
|
| Actins | 4 | 2015 | 461 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 188 | 0.380 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 45 | 0.370 |
Why?
|
| Trans-Activators | 3 | 2022 | 443 | 0.360 |
Why?
|
| Reticulocytes | 2 | 2010 | 25 | 0.360 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1668 | 0.360 |
Why?
|
| Phosphoproteins | 2 | 2022 | 260 | 0.340 |
Why?
|
| Malaria, Falciparum | 1 | 2009 | 12 | 0.340 |
Why?
|
| Cells, Cultured | 20 | 2013 | 2884 | 0.340 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 2002 | 11 | 0.330 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 1221 | 0.320 |
Why?
|
| Multigene Family | 1 | 2009 | 202 | 0.320 |
Why?
|
| Antigens, CD34 | 12 | 2017 | 159 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 585 | 0.300 |
Why?
|
| Osteopontin | 1 | 2008 | 47 | 0.300 |
Why?
|
| RNA, Messenger | 10 | 2009 | 2021 | 0.290 |
Why?
|
| Blood Component Removal | 3 | 2020 | 24 | 0.290 |
Why?
|
| Animals | 30 | 2022 | 27481 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 449 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 226 | 0.280 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 2582 | 0.280 |
Why?
|
| Hematologic Neoplasms | 7 | 2016 | 344 | 0.280 |
Why?
|
| Cytoskeleton | 1 | 2008 | 195 | 0.270 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 2021 | 30 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2016 | 50 | 0.260 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 3 | 2019 | 13 | 0.250 |
Why?
|
| Receptors, Erythropoietin | 5 | 1999 | 14 | 0.240 |
Why?
|
| GATA1 Transcription Factor | 3 | 2017 | 18 | 0.240 |
Why?
|
| Blood Donors | 2 | 2016 | 22 | 0.240 |
Why?
|
| Forkhead Transcription Factors | 5 | 2016 | 171 | 0.240 |
Why?
|
| MicroRNAs | 1 | 2009 | 555 | 0.240 |
Why?
|
| Syndecan-1 | 2 | 2018 | 16 | 0.240 |
Why?
|
| Integrin beta1 | 2 | 2018 | 33 | 0.240 |
Why?
|
| Haplotypes | 4 | 2016 | 637 | 0.240 |
Why?
|
| Globins | 3 | 2021 | 31 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2013 | 387 | 0.230 |
Why?
|
| Transplantation, Homologous | 12 | 2016 | 995 | 0.230 |
Why?
|
| Cell Division | 5 | 2002 | 692 | 0.230 |
Why?
|
| Caspase 3 | 4 | 2019 | 162 | 0.220 |
Why?
|
| Base Sequence | 8 | 2012 | 2329 | 0.220 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2003 | 19 | 0.220 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 538 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2012 | 268 | 0.210 |
Why?
|
| Graft vs Host Disease | 8 | 2017 | 358 | 0.210 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 28 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 1999 | 46 | 0.210 |
Why?
|
| Mice | 20 | 2022 | 11832 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 191 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2013 | 693 | 0.200 |
Why?
|
| Epigenomics | 2 | 2020 | 103 | 0.200 |
Why?
|
| Cell Line | 10 | 2021 | 2494 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 162 | 0.190 |
Why?
|
| Interferon-alpha | 3 | 2013 | 214 | 0.190 |
Why?
|
| Interferon-beta | 3 | 2013 | 126 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2016 | 166 | 0.190 |
Why?
|
| Cytoskeletal Proteins | 2 | 2009 | 228 | 0.190 |
Why?
|
| Potassium Channels | 1 | 2003 | 346 | 0.180 |
Why?
|
| Protein Binding | 5 | 2019 | 1491 | 0.180 |
Why?
|
| Erythrocyte Membrane | 3 | 2010 | 61 | 0.180 |
Why?
|
| Forkhead Box Protein O3 | 3 | 2008 | 21 | 0.180 |
Why?
|
| Biomarkers | 3 | 2019 | 1768 | 0.180 |
Why?
|
| Flow Cytometry | 7 | 2016 | 689 | 0.180 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 184 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1281 | 0.170 |
Why?
|
| Male | 24 | 2018 | 42488 | 0.170 |
Why?
|
| Leukemia | 3 | 2012 | 322 | 0.170 |
Why?
|
| Models, Biological | 4 | 2019 | 1762 | 0.170 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2010 | 45 | 0.170 |
Why?
|
| Bone Marrow | 3 | 2018 | 443 | 0.170 |
Why?
|
| Polycythemia Vera | 1 | 1999 | 23 | 0.170 |
Why?
|
| Unrelated Donors | 2 | 2017 | 45 | 0.170 |
Why?
|
| Fetal Blood | 2 | 2017 | 93 | 0.160 |
Why?
|
| Dynamin III | 1 | 2018 | 1 | 0.160 |
Why?
|
| Dynamin II | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cell Movement | 2 | 2019 | 785 | 0.160 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2021 | 242 | 0.160 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 45 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2000 | 114 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 86 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 158 | 0.150 |
Why?
|
| Isoenzymes | 4 | 2009 | 274 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 2018 | 92 | 0.150 |
Why?
|
| Kinetics | 5 | 2003 | 1534 | 0.150 |
Why?
|
| Gene Expression | 4 | 2020 | 1309 | 0.150 |
Why?
|
| Graft Survival | 6 | 2016 | 902 | 0.150 |
Why?
|
| Female | 23 | 2018 | 46401 | 0.150 |
Why?
|
| Alternative Splicing | 2 | 2009 | 212 | 0.150 |
Why?
|
| Mice, Knockout | 5 | 2018 | 2014 | 0.140 |
Why?
|
| Thrombopoiesis | 1 | 2017 | 5 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 260 | 0.140 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2015 | 48 | 0.140 |
Why?
|
| DNA Methylation | 4 | 2017 | 663 | 0.140 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 3 | 2010 | 14 | 0.140 |
Why?
|
| Leukapheresis | 1 | 2016 | 20 | 0.140 |
Why?
|
| Aged | 18 | 2017 | 19158 | 0.140 |
Why?
|
| Wnt Proteins | 1 | 2017 | 130 | 0.140 |
Why?
|
| Ferritins | 1 | 2016 | 29 | 0.140 |
Why?
|
| Primary Myelofibrosis | 1 | 2017 | 67 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 885 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2018 | 725 | 0.140 |
Why?
|
| Vidarabine | 4 | 2005 | 144 | 0.130 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Enzyme Activation | 5 | 2009 | 696 | 0.130 |
Why?
|
| Serum Albumin | 1 | 2016 | 127 | 0.130 |
Why?
|
| Molecular Chaperones | 2 | 2009 | 123 | 0.130 |
Why?
|
| NADPH Dehydrogenase | 1 | 2015 | 11 | 0.130 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 21 | 0.130 |
Why?
|
| Anemia | 2 | 2014 | 129 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 565 | 0.130 |
Why?
|
| beta Catenin | 1 | 2017 | 266 | 0.130 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2015 | 6 | 0.130 |
Why?
|
| Recombinant Proteins | 6 | 2009 | 1008 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2017 | 520 | 0.120 |
Why?
|
| Middle Aged | 20 | 2017 | 26012 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 529 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2015 | 86 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 699 | 0.120 |
Why?
|
| Chromosome Deletion | 2 | 2017 | 227 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 1048 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2017 | 1498 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 326 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2016 | 227 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2002 | 449 | 0.120 |
Why?
|
| Transcription, Genetic | 5 | 2009 | 1158 | 0.120 |
Why?
|
| Cytosine | 3 | 2022 | 129 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 33 | 0.120 |
Why?
|
| Zebrafish Proteins | 1 | 2015 | 149 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 63 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 39 | 0.110 |
Why?
|
| Neuropeptides | 1 | 1994 | 115 | 0.110 |
Why?
|
| Tropomodulin | 1 | 2013 | 1 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 312 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 447 | 0.110 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2013 | 18 | 0.110 |
Why?
|
| Adult | 18 | 2016 | 26704 | 0.110 |
Why?
|
| Young Adult | 9 | 2016 | 6368 | 0.110 |
Why?
|
| Cluster Analysis | 2 | 2015 | 370 | 0.110 |
Why?
|
| CCAAT-Binding Factor | 1 | 2012 | 1 | 0.110 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 154 | 0.110 |
Why?
|
| Zebrafish | 1 | 2015 | 320 | 0.110 |
Why?
|
| gamma-Globins | 1 | 2012 | 5 | 0.110 |
Why?
|
| RNA Precursors | 2 | 2009 | 72 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 233 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 341 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2012 | 423 | 0.100 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 84 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 2503 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 3024 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 663 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 187 | 0.100 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2002 | 24 | 0.100 |
Why?
|
| Transplantation Chimera | 2 | 2009 | 81 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2002 | 341 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2012 | 312 | 0.090 |
Why?
|
| Liver | 2 | 2013 | 1208 | 0.090 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 133 | 0.090 |
Why?
|
| Smad7 Protein | 1 | 2010 | 7 | 0.090 |
Why?
|
| Adolescent | 10 | 2016 | 9305 | 0.090 |
Why?
|
| Growth Inhibitors | 2 | 2002 | 41 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 79 | 0.090 |
Why?
|
| Age Factors | 3 | 2012 | 1877 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 86 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 288 | 0.090 |
Why?
|
| DNA | 5 | 2003 | 1310 | 0.090 |
Why?
|
| Leukocytes | 1 | 2011 | 208 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1072 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 316 | 0.090 |
Why?
|
| Mutation | 6 | 2022 | 4160 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2010 | 150 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 1999 | 10 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 173 | 0.080 |
Why?
|
| Host-Parasite Interactions | 1 | 2009 | 30 | 0.080 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 19 | 0.080 |
Why?
|
| CpG Islands | 3 | 2017 | 158 | 0.080 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 52 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 54 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2009 | 149 | 0.080 |
Why?
|
| Thiadiazoles | 1 | 2008 | 12 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 42 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2003 | 125 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 49 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 54 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2012 | 496 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 91 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 975 | 0.080 |
Why?
|
| Integrin alpha4 | 1 | 2008 | 11 | 0.080 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 249 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 431 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 38 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2009 | 267 | 0.070 |
Why?
|
| Binding Sites | 4 | 2013 | 1120 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2009 | 186 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 109 | 0.070 |
Why?
|
| Spectrin | 3 | 2001 | 15 | 0.070 |
Why?
|
| RNA, Transfer | 1 | 2009 | 160 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 260 | 0.070 |
Why?
|
| Heme | 2 | 1999 | 64 | 0.070 |
Why?
|
| Health Status | 1 | 2009 | 371 | 0.070 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 28 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1227 | 0.070 |
Why?
|
| K562 Cells | 3 | 2012 | 44 | 0.070 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 137 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 174 | 0.070 |
Why?
|
| Genome, Human | 2 | 2013 | 791 | 0.070 |
Why?
|
| Heat-Shock Proteins | 2 | 2007 | 183 | 0.070 |
Why?
|
| Cell Survival | 3 | 2018 | 983 | 0.070 |
Why?
|
| Prognosis | 4 | 2016 | 3785 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2022 | 276 | 0.070 |
Why?
|
| Living Donors | 1 | 2009 | 339 | 0.070 |
Why?
|
| Stem Cells | 4 | 2013 | 375 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2004 | 231 | 0.060 |
Why?
|
| Cell Separation | 2 | 2016 | 199 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1394 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 1541 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 484 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 2001 | 258 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2004 | 996 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2012 | 1172 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2009 | 383 | 0.060 |
Why?
|
| Receptors, Purinergic | 1 | 2004 | 6 | 0.060 |
Why?
|
| Tetrodotoxin | 1 | 2004 | 50 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 306 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2001 | 33 | 0.060 |
Why?
|
| Chromatin | 2 | 2019 | 402 | 0.060 |
Why?
|
| Receptors, Muscarinic | 1 | 2004 | 48 | 0.060 |
Why?
|
| Protein Transport | 3 | 2012 | 421 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 2 | 2005 | 40 | 0.060 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 2003 | 2 | 0.060 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 2003 | 10 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 188 | 0.060 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2003 | 33 | 0.060 |
Why?
|
| Pregnancy | 1 | 2011 | 3038 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2016 | 8218 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2003 | 86 | 0.060 |
Why?
|
| Sodium Channels | 1 | 2004 | 130 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2004 | 241 | 0.060 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2003 | 5 | 0.060 |
Why?
|
| Caspases | 2 | 2000 | 155 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2003 | 66 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 98 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2003 | 49 | 0.050 |
Why?
|
| Premedication | 1 | 2003 | 58 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 188 | 0.050 |
Why?
|
| Friend murine leukemia virus | 2 | 1993 | 5 | 0.050 |
Why?
|
| Acute Disease | 3 | 2012 | 842 | 0.050 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Acyclovir | 1 | 2003 | 108 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 557 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 135 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 558 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 154 | 0.050 |
Why?
|
| Remission Induction | 3 | 2011 | 740 | 0.050 |
Why?
|
| Anemia, Aplastic | 1 | 2002 | 32 | 0.050 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2002 | 79 | 0.050 |
Why?
|
| RNA Interference | 2 | 2018 | 376 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 2 | 2001 | 65 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 149 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 261 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2009 | 293 | 0.050 |
Why?
|
| Acetylation | 1 | 2002 | 132 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 407 | 0.050 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2012 | 12 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2018 | 675 | 0.050 |
Why?
|
| Clathrin | 2 | 2012 | 29 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 197 | 0.050 |
Why?
|
| Interferons | 1 | 2001 | 127 | 0.050 |
Why?
|
| Vacuoles | 2 | 2012 | 46 | 0.050 |
Why?
|
| Time Factors | 5 | 2009 | 5337 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 3054 | 0.050 |
Why?
|
| Histocompatibility | 2 | 2016 | 65 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2001 | 133 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2022 | 156 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2003 | 144 | 0.050 |
Why?
|
| Chromones | 1 | 2000 | 31 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2009 | 466 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2000 | 58 | 0.040 |
Why?
|
| Fetus | 1 | 2021 | 232 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 51 | 0.040 |
Why?
|
| Family | 2 | 2012 | 325 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 153 | 0.040 |
Why?
|
| Morpholines | 1 | 2000 | 70 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 484 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2022 | 284 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 740 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 33 | 0.040 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1999 | 3 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 368 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1576 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1999 | 88 | 0.040 |
Why?
|
| Milk Proteins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 2063 | 0.040 |
Why?
|
| Sirolimus | 1 | 2000 | 162 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 399 | 0.040 |
Why?
|
| Melphalan | 3 | 2005 | 98 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 952 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 1999 | 79 | 0.040 |
Why?
|
| DNA Primers | 3 | 2009 | 543 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 465 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 195 | 0.040 |
Why?
|
| RNA | 1 | 2003 | 583 | 0.040 |
Why?
|
| Filgrastim | 2 | 2009 | 57 | 0.040 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 26 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2018 | 85 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 198 | 0.040 |
Why?
|
| Protein Kinases | 1 | 1999 | 212 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 259 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6771 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 961 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 98 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2009 | 85 | 0.040 |
Why?
|
| Exons | 2 | 2009 | 453 | 0.040 |
Why?
|
| Risk Factors | 3 | 2016 | 5517 | 0.040 |
Why?
|
| Recurrence | 2 | 2016 | 1143 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 9 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 976 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 45 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 37 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 508 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 197 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 133 | 0.030 |
Why?
|
| Siblings | 2 | 2009 | 110 | 0.030 |
Why?
|
| Chimerism | 1 | 2016 | 37 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2012 | 948 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 223 | 0.030 |
Why?
|
| Thy-1 Antigens | 1 | 1995 | 16 | 0.030 |
Why?
|
| DNA Probes | 2 | 1994 | 77 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 2356 | 0.030 |
Why?
|
| Mitosis | 1 | 2016 | 152 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2009 | 272 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.030 |
Why?
|
| Hypoxia | 1 | 2020 | 656 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 2008 | 346 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 66 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1995 | 216 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
| Ankyrins | 1 | 1994 | 23 | 0.030 |
Why?
|
| Microfilament Proteins | 2 | 2009 | 212 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1798 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 311 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 970 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 183 | 0.030 |
Why?
|
| Enzyme Inhibitors | 3 | 2002 | 642 | 0.030 |
Why?
|
| Child | 2 | 2022 | 7216 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 115 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 1993 | 1 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1993 | 71 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1994 | 100 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2013 | 17 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 153 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 849 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 336 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 165 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2013 | 23 | 0.030 |
Why?
|
| Incidence | 2 | 2011 | 1598 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 152 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1994 | 113 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 13 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 66 | 0.030 |
Why?
|
| TATA Box | 1 | 2012 | 11 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 98 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1992 | 36 | 0.030 |
Why?
|
| GATA2 Transcription Factor | 1 | 2012 | 14 | 0.030 |
Why?
|
| Half-Life | 1 | 1992 | 97 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 117 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2012 | 49 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 50 | 0.030 |
Why?
|
| Coated Pits, Cell-Membrane | 1 | 2012 | 6 | 0.030 |
Why?
|
| Telomerase | 1 | 2012 | 67 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 98 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 82 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1992 | 193 | 0.020 |
Why?
|
| Methylation | 1 | 2013 | 269 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2009 | 951 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 301 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1463 | 0.020 |
Why?
|
| Survival Rate | 2 | 2008 | 1887 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 952 | 0.020 |
Why?
|
| Nocodazole | 1 | 2010 | 18 | 0.020 |
Why?
|
| Monensin | 1 | 2010 | 16 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 394 | 0.020 |
Why?
|
| Diffusion | 1 | 2010 | 93 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 476 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 262 | 0.020 |
Why?
|
| DNA Polymerase II | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2009 | 6 | 0.020 |
Why?
|
| Splicing Factor U2AF | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2009 | 79 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 38 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 247 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 134 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2009 | 52 | 0.020 |
Why?
|
| Endocytosis | 1 | 2010 | 180 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
| Calnexin | 1 | 2009 | 4 | 0.020 |
Why?
|
| Calreticulin | 1 | 2009 | 13 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 11 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2009 | 16 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2009 | 14 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 433 | 0.020 |
Why?
|
| Galactolipids | 1 | 1988 | 2 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 80 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2009 | 27 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2012 | 678 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2016 | 9127 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3240 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 36 | 0.020 |
Why?
|
| Acyltransferases | 1 | 1988 | 41 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 870 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 96 | 0.020 |
Why?
|
| Pteridines | 1 | 2008 | 4 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 369 | 0.020 |
Why?
|
| Lentivirus | 1 | 2008 | 43 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 194 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1862 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 453 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7050 | 0.020 |
Why?
|
| Cyanobacteria | 1 | 1988 | 113 | 0.020 |
Why?
|
| Lymphoma | 1 | 2009 | 266 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 126 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2384 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 919 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 255 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 775 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 388 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 234 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 277 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 242 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 282 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 895 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2878 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 370 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 563 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 743 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 394 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2004 | 48 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 309 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 645 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 205 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1727 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 793 | 0.010 |
Why?
|
| Thiotepa | 1 | 2003 | 32 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 786 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 194 | 0.010 |
Why?
|
| Viremia | 1 | 2003 | 49 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 848 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2002 | 20 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 278 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 112 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 35 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2001 | 56 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 77 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2001 | 156 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 84 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 140 | 0.010 |
Why?
|
| Vanadates | 1 | 2000 | 32 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 22 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 36 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2000 | 20 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 34 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 49 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 63 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 269 | 0.010 |
Why?
|
| Pyridines | 1 | 2001 | 298 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 37 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-crk | 1 | 1999 | 10 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1999 | 32 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 481 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1705 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 67 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 1999 | 43 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 53 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1928 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 289 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 4309 | 0.010 |
Why?
|
| Countercurrent Distribution | 1 | 1995 | 2 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1995 | 6 | 0.010 |
Why?
|
| Centrifugation | 1 | 1995 | 24 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 1995 | 18 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 1995 | 12 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1995 | 7 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 66 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1995 | 35 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 97 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1995 | 133 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 111 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 2449 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1995 | 141 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 6 | 0.010 |
Why?
|
| Hemin | 1 | 1994 | 5 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1995 | 301 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1995 | 782 | 0.010 |
Why?
|
| Acyl Carrier Protein | 1 | 1988 | 8 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1988 | 25 | 0.010 |
Why?
|
| Diglycerides | 1 | 1988 | 22 | 0.010 |
Why?
|
| Coenzyme A | 1 | 1988 | 15 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1988 | 42 | 0.010 |
Why?
|
| Glycolipids | 1 | 1988 | 29 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 315 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1988 | 316 | 0.000 |
Why?
|